Replacing mealtime insulin with weekly semaglutide missed its primary glycaemic target (90% vs 75%, p=0.18) but cut weight and insulin dose in this small open-label trial. PICO summary and expert commentary.
Browsing: PICO
Structured PICO summaries for doctors and healthcare professionals, covering population, intervention, comparison, outcomes, expert commentary, and references across diabetes, endocrinology, obesity, and cardiometabolic medicine.
In children aged 2-6 years with type 1 diabetes, the MiniMed 780G in auto mode improved time in range and HbA1c over manual mode with suspend-before-low, meeting non-inferiority with superiority. PICO summary and expert commentary.
A prespecified STRIDE subgroup analysis examined whether once-weekly semaglutide 1.0 mg improves walking distance consistently across diabetes characteristics in 792 adults with symptomatic PAD and type 2 diabetes. PICO summary and expert commentary.
A secondary patient-reported-outcomes analysis of the SURMOUNT-1 phase 3 trial finds tirzepatide improved health-related quality of life versus placebo in adults with obesity, with larger gains at greater weight loss. PICO summary and expert commentary.
An industry-sponsored indirect treatment comparison suggesting tirzepatide 10 and 15 mg achieve greater weight, BMI and HbA1c reduction than semaglutide 2.4 mg in type 2 diabetes, with no head-to-head trial. PICO summary and expert commentary.
A phase 1 first-in-human study of the oral GLP-1 receptor agonist ECC5004/AZD5004 in healthy volunteers and T2DM patients found it well tolerated with early dose-dependent glucose and weight signals. PICO summary and expert commentary.
A 13-week randomised trial found automated insulin delivery sharply lowered HbA1c in youth with type 1 diabetes but objectively reduced sleep efficiency and increased night-time wakefulness. PICO summary and expert commentary.
A 6-month randomised trial in older adults with type 2 diabetes found home telemedicine plus Health Belief Model education cut HbA1c by 0.42% more than usual care. PICO summary and expert commentary.
In 28 AID-naive adults with type 1 diabetes, a tubeless open-source hybrid loop (AndroidAPS) raised time in range to 75.6 percent versus 60.4 percent on sensor-augmented pump therapy without added hypoglycaemia. PICO summary and expert commentary.
Summary: In adults with obesity, exposure to GLP-1 receptor agonists and bariatric surgery significantly increased policy support for obesity treatments…